Search

everythinglearnresearchcommunity

for

Search:↓

Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

The document concludes that understanding genetic mutations in the PI3K-AKT-mTOR pathway can lead to better diagnosis and treatment for certain genetic skin disorders.

WYE-130600 may cause skin thickening and irritation.

AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.

Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

Ritlecitinib is cost-effective for severe alopecia areata in Japan.

The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.

Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.

Tofacitinib is effective and safe for treating severe alopecia areata.

Tofacitinib may help treat severe hair loss, but more research is needed.

Ruxolitinib cream may help treat severe hair loss in children.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Hedgehog pathway inhibitors could be effective in treating melanoma.

Decreasing MIG6 can increase the movement and invasiveness of MEK-inhibited mutant NRAS melanoma, particularly when stimulated by EGF.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Upadacitinib successfully treated a child's severe skin and hair loss issues.